iOnctura develops precision oral small molecules targeting neglected and hard-to-treat cancers by modulating key signaling pathways, including allosteric modulation of PI3Kδ and inhibition of autotaxin. Their therapies aim to reduce the severe side effects associated with conventional treatments, thereby improving patient healthspan and overall survival.
Funding
$159.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers, particularly neglected and hard-to-treat types, have limited effective treatment options, and existing therapies often cause severe side effects, reducing patients' quality of life and overall survival. These cancers are frequently burdened by stroma and immune-mediated resistance, making them difficult to target.
Solution
iOnctura is developing precision oral small molecules designed to target key signaling pathways involved in cancer progression, with a focus on allosteric modulation of PI3Kδ and inhibition of autotaxin (ATX). Their therapeutic approach aims to disrupt the dynamic interplay at the heart of the tumor-stroma-immune interface, creating high-impact, low-disruption therapies. By modulating these pathways, iOnctura seeks to develop more effective and less toxic treatments that reduce the severe side effects associated with conventional cancer therapies, ultimately improving patient healthspan and overall survival. The company's pipeline includes molecules with unique mechanisms of action, such as allosteric modulation and dual catalytic/chaperone inhibition, to overcome resistance and improve treatment outcomes.
Target Audience
iOnctura's therapies target patients with neglected and hard-to-treat cancers, particularly those with tumors exhibiting stroma and immune-mediated resistance.
Features
- Roginolisib (IOA-244): A first-in-class oral allosteric modulator of PI3Kδ with a unique chemical structure and binding mode, currently in clinical trials.
- Cambritaxestat (IOA-289): A clinical-stage autotaxin (ATX) inhibitor that distinctively inhibits both the catalytic and chaperone activities of the enzyme.
- IOA-359: A novel small molecule TGF-β pathway inhibitor designed to address tumor aggressiveness, immune escape, and resistance to therapy.
- Designed to be low toxicity and gentle on the body, yet powerful in disrupting and inhibiting tumors.